FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

<b>STATEMENT</b>	OF CHANGE	S IN BENEF	ICIAL OW	/NFRSHIP
SIAILMLNI	OI CITAINOL	O III DEILE	ICIAL CV	

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average I	ourden							
hours per response.	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  HEALY JAMES  (Last) (First) (Middle)  C/O SOFINNOVA INVESTMENTS INC.  3000 SAND HILL ROAD, BLDG. 4, SUITE 250					3. I 06	2. Issuer Name and Ticker or Trading Symbol Y-mAbs Therapeutics, Inc. [ YMAB ]  3. Date of Earliest Transaction (Month/Day/Year) 06/10/2020  4. If Amendment, Date of Original Filed (Month/Day/Year)								Relationship of Reporting Person(s) to Issuer Check all applicable)  X Director 10% Owner Officer (give title below)  Other (specify below)  Individual or Joint/Group Filing (Check Applicable				ner
(Street) MENLO (City)	PARK C.	tate)	94025 (Zip)	ı-Deriv								Line	X Form filed by One Reporting Person Form filed by More than One Reporting Person					
1. Title of Security (Instr. 3)  2. Transa Date (Month/D			action	2A. Deemed Execution Date,		3. Transact Code (In 8)	ion str.	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)		d (A) or	5. Amour Securitie Beneficia	nt of 6. Owes Form (D) of ollowing (I) (In		: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execution Date, Gecurity or Exercise (Month/Day/Year) if any		ate,		ransaction of ode (Instr. Derivative		ve es d	6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)		Date Exercisable		Expiration Date	Title	Amount or Number of Shares					
Non- Employee Stock Option (right to buy) <sup>(1)</sup>	\$37.53	06/10/2021			A		16,000		07/10/2021 <sup>(2</sup>	2) (	06/10/2031	Common stock	16,000	\$0	16,000	0	D	

## Explanation of Responses:

- 1. Stock options granted to the Reporting Person as a non-employee director pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc.
- 2. The stock options vest in equal monthly installments during the first year following the date of grant, subject to the Reporting Person's continued service on the board of directors of Y-mAbs Therapeutics, Inc., and are exercisable immediately upon vesting.

/s/ James Healy

06/11/2021

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.